Company news

Botanix Pharmaceuticals Limited news in 2018

Botanix Pharmaceuticals Limited's news releases, calls and decks from 2018, newest first.

View company

Ethics Approval for Phase 2 Atopic Dermatitis Study Received

December 17, 2018

Botanix receives A$4.6m R&D Tax Incentive refund

November 22, 2018

First Patient Treated in BTX 1308 Psoriasis Patient Study

November 6, 2018

Ethics Approval for BTX 1308 Psoriasis Patient Study Secured

September 26, 2018

Botanix BTX 1503 Clinical Trial Update

September 12, 2018

FDA Clears Development Path for BTX 1204

August 29, 2018

Investigators Meeting Completed for BTX 1503 Phase 2 Trial

July 22, 2018

Botanix Joins with UQ to Accelerate Development of BTX 1801

July 18, 2018

Botanix update on development pipeline products

July 1, 2018

First Patients Recruited into BTX 1503 Phase 2 Acne Trial

June 26, 2018

BOT Welcomes First FDA Approval for Cannabidiol Product

June 25, 2018

Botanix Raises A$8m in Oversubscribed Placement

June 20, 2018

Australian Ethics approval for Acne Study

June 12, 2018

BTX 1204 Atopic Dermatitis Study Results Presentation

June 6, 2018

Botanix Announces Successful Atopic Dermatitis Study Results

June 5, 2018

Presentation on Atopic Dermatitis Market

May 22, 2018

FDA Green Light for BTX 1503 Phase 2 Study

May 7, 2018

Appendix 4C - quarterly

April 24, 2018

Enrolment of BTX 1204 Atopic Dermatitis Study Completed

April 9, 2018

Completion of Placement

February 11, 2018

Significantly Oversubscribed A$15m Placement

February 4, 2018

Botanix Announces Successful Acne Study Results

January 28, 2018

Botanix Receives A$1.6m R&D Tax Incentive Refund

January 15, 2018

Decks in 2018